Journal article
Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer.
-
Bell R
Faculty of Medicine, Deakin University, Geelong, Australia.
-
Brown J
Clinical Trials Research Unit, University of Leeds, Leeds.
-
Parmar M
Medical Research Council Clinical Trials Unit, London, UK.
-
Toi M
Faculty of Medicine, Kyoto University, Kyoto, Japan.
-
Suter T
Swiss Cardiovascular Center, Bern University Hospital, Bern, Switzerland.
-
Steger GG
Department of Internal Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria.
-
Pivot X
Medical Oncology Service, University Hospital Jean Minjoz, Besançon, France.
-
Mackey J
Medical Oncology, Cross Center Institute, Edmonton, Canada.
-
Jackisch C
Department of Obstetrics and Gynecology and Breast Cancer Center, Sana Klinikum Offenbach, Offenbach, Germany.
-
Dent R
Department of Medical Oncology, National Cancer Center, Singapore, Singapore, and Sunnybrook Health Sciences Center, University of Toronto, Toronto, Canada.
-
Hall P
Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
-
Xu N
Product Development Oncology, F Hoffmann-La Roche Ltd, Basel, Switzerland.
-
Morales L
Product Development Oncology, F Hoffmann-La Roche Ltd, Basel, Switzerland.
-
Provencher L
Centre des Maladies du Sein Deschênes-Fabia, CHU de Québec-Hôpital du Saint-Sacrement, Ville de Québec, Québec, Canada.
-
Hegg R
Oncology Department, Perola Byington Hospital/FMUSP, São Paulo, Brazil.
-
Vanlemmens L
Department of Medical Oncology, Centre Oscar Lambret, Lille, France.
-
Kirsch A
Onkologischer Schwerpunktam Oskar-Helene-Heim, Berlin, Germany.
-
Schneeweiss A
Division of Gynecologic Oncology, National Center for Tumor Diseases, University Hospital, Heidelberg, Germany.
-
Masuda N
Department of Surgery, Breast Oncology NHO Osaka National Hospital, Osaka, Japan.
-
Overkamp F
Oncologianova, Recklinghausen, Germany.
-
Cameron D
Edinburgh University Cancer Research Centre, University of Edinburgh and Cancer Services, NHS Lothian, Edinburgh, UK.
Show more…
Published in:
- Annals of oncology : official journal of the European Society for Medical Oncology. - 2017
English
Background
The purpose of this analysis was to assess the long-term impact of adding bevacizumab to adjuvant chemotherapy for early triple-negative breast cancer (TNBC).
Methods
Patients eligible for the open-label randomized phase III BEATRICE trial had centrally confirmed triple-negative operable primary invasive breast cancer (pT1a-pT3). Investigators selected anthracycline- and/or taxane-based chemotherapy for each patient. After definitive surgery, patients were randomized 1:1 to receive ≥4 cycles of chemotherapy alone or with 1 year of bevacizumab (5 mg/kg/week equivalent). Stratification factors were nodal status, selected chemotherapy, hormone receptor status, and type of surgery. The primary end point was invasive disease-free survival (IDFS; previously reported). Secondary outcome measures included overall survival (OS) and safety.
Results
After 56 months' median follow-up, 293 of 2591 randomized patients had died. There was no statistically significant difference in OS between treatment arms in either the total population (hazard ratio 0.93, 95% confidence interval [CI] 0.74-1.17; P = 0.52) or pre-specified subgroups. The 5-year OS rate was 88% (95% CI 86-90%) in both treatment arms. Updated IDFS results were consistent with the primary IDFS analysis. Five-year IDFS rates were 77% (95% CI 75-79%) with chemotherapy alone versus 80% (95% CI 77-82%) with bevacizumab. From 18 months after first study dose to study end, new grade ≥3 adverse events occurred in 4.6% and 4.5% of patients in the two arms, respectively.
Conclusion
Final OS results showed no significant benefit from bevacizumab therapy for early TNBC. Late-onset toxicities were rare in both groups. Five-year OS and IDFS rates suggest that the prognosis for patients with TNBC is better than previously thought.
ClinicalTrials.gov
NCT00528567.
-
Language
-
-
Open access status
-
bronze
-
Identifiers
-
-
Persistent URL
-
https://sonar.ch/global/documents/185054
Statistics
Document views: 16
File downloads: